Erlotinib-d8

Erlotinib-d8 (CP-358774-d8) is deuterium labeled Erlotinib. Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer[1]. Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

1266656-97-6

CP-358774-d8; NSC 718781-d8; OSI-774-d8

12352005

Isotope-Labeled Compounds

Others

Cancer-programmed cell death

Cancer

COC([2H])([2H])C([2H])([2H])OC(C(OC([2H])([2H])C([2H])([2H])OC)=C1)=CC2=C1C(NC3=CC(C#C)=CC=C3)=NC=N2

C22H15D8N3O4

401.49

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-50896S3/

Isotope-Labeled Compounds

No Development Reported